A Dose-Finding Study of RO4998452 in Patients With Diabetes Mellitus

Change From Baseline in Fasting Plasma Glucose (mmol/L)

Time frame: Baseline and Week 12

Change From Baseline in Mean Daily Glucose Concentration (mmol/L)

Time frame: Baseline and Week 12

Change From Baseline in Fructosamine Concentration (μmol/L)

Time frame: Baseline and 12 weeks

Change From Baseline in Meal Tolerance Test: 0-3h Mean Glucose Concentration (mmol/L)

Time frame: Baseline and Week 12

Change From Baseline in Meal Tolerance Test: 0-3h Mean Insulin Concentration (mmol/L)

Time frame: Baseline and Week 12

Change From Baseline in Meal Tolerance Test: 0-3h Urinary Glucose Excretion (mmol/L)

Time frame: Baseline and Week 12

Change From Baseline in Body Weight (kg)

Time frame: Baseline and Week 12

Percentage of Participants Treated to Target HbA1c < 7%

Time frame: Baseline up to 12 weeks

Percentage of Participants Treated to Target HbA1c < 6.5%

Time frame: Baseline up to 12 weeks

Percentage of Participants With at Least One Adverse Event